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Abstract
Background: Despite the high cardiovascular risk, evidence of efficacy of preventive strategies in
individuals with diabetes is scant. In particular, recommendations on the use of aspirin in patients
with diabetes mostly reflect an extrapolation from data deriving from other high risk populations.
Furthermore, the putative additive effects of aspirin and statins in diabetes remain to be
investigated. This aspect is of particular interest in the light of the existing debate regarding the
need of multiple interventions to reduce total cardiovascular risk, which has also led to the
proposal of a polypill. Aim of the study is to evaluate the efficacy of aspirin in the primary prevention
of major cardiovascular events in diabetic patients candidate for treatment with statins. These
preventive strategies will be evaluated on the top of the other strategies aimed at optimizing the
care of diabetic patients in terms of metabolic control and control of the other cardiovascular risk
factors.
Methods/Design: The ACCEPT-D is an open-label trial assessing whether 100 mg/daily of aspirin
prevent cardiovascular events in patients without clinically manifest vascular disease and treated
with simvastatin (starting dose 20 mg/die). Eligible patients will be randomly assigned to receive
aspirin + simvastatin or simvastatin alone. Eligibility criteria: male and female individuals aged >=50
years with diagnosis of type 1 or type 2 diabetes, already on treatment with statins or candidate to
start the treatment (LDL-cholesterol >=100 mg/dL persisting after 3 months of dietary advise). The
primary combined end-point will include cardiovascular death, non-fatal myocardial infarction, non-
fatal stroke, and hospital admission for cardiovascular causes (acute coronary syndrome, transient
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ischemic attack, not planned revascularization procedures, peripheral vascular disease). A total of
515 first events are needed to detect a reduction in the risk of major cardiovascular events of 25%
(alpha = 0.05; 1-beta = 0.90). Overall, 5170 patients will be enrolled. The study will be conducted
by diabetes specialists and general practitioners.
Discussion: The study will provide important information regarding the preventive role of aspirin
in diabetes when used on the top of the other strategies aimed to control cardiovascular risk
factors.
Trial registration: Current Controlled Trials ISRCTN48110081.
Background
Macrovascular complications represent the leading cause
of morbidity, mortality, and resource consumption in
type 2 diabetes, and their burden is expected to grow in
the next years due to the increasing incidence of the dis-
ease worldwide.
Individuals with type 2 diabetes have a two- to fourfold
increased risk of cardiovascular disease (CVD) compared
with non-diabetic subjects and CVD mortality rates are
1.5–4.5 times higher than in the general population [1].
The increase in the incidence of coronary events is greater
for more severe clinical outcomes, such as myocardial inf-
arction and sudden death, than for less serious outcomes,
such as angina pectoris [1]. Furthermore, the case fatality
rate after a myocardial infarction among individuals with
diabetes is higher than that for patients without diabetes;
after a first cardiac event, 50% of patients with diabetes
die within one year, and half of those who die do so
before they reach the hospital (sudden deaths) [2]. The
high incidence of sudden deaths makes primary preven-
tion particularly relevant in this population. In addition,
it has been shown that diabetic patients without previous
myocardial infarction have as high a risk of myocardial
infarction as non-diabetic patients with previous myocar-
dial infarction [3]. These findings make the differentiation
between primary and secondary prevention in individuals
with diabetes almost irrelevant and suggest the need for
treating cardiovascular risk factors aggressively.
Despite the very high cardiovascular risk profile, evidence
of efficacy of preventive strategies in individuals with dia-
betes is surprisingly scant. In particular, the existing rec-
ommendations [4] regarding the use of aspirin and statins
for the prevention of cardiovascular events in patients
with diabetes reflect more an extrapolation from data
deriving from other high risk populations, rather than
reliable evidence based on studies specifically designed
for individuals with diabetes. The substantial lack of clear
evidence is reflected by the low use of this drug in clinical
practice; in fact, only 10% of diabetic patients are treated
with aspirin for the prevention of cardiovascular events
[5].
While the efficacy of aspirin versus placebo in patients
with diabetes is currently under investigation, the putative
additive effects of aspirin and statins in this population
remain to be investigated. This aspect is of particular inter-
est in the light of the existing debate regarding the need of
multiple interventions to reduce total cardiovascular risk,
which has also led to the proposal of a polypill [6]. To this
respect, a recent nested case-control study suggests that
the greater benefit in terms of mortality reduction in
patients with ischemic heart disease is achieved when the
multiple drug intervention included statins, aspirin and β-
blockers and/or ACE-inhibitors [7]. Nevertheless, no spe-
cific information is available for patients with diabetes
mellitus, for whom there is the suspicion that aspirin
could be less effective [8], making additional research
urgently needed.
This situation is particularly worrisome when considering
that a tight metabolic control, while representing a corner-
stone of diabetes care, is not per se sufficient to substan-
tially decrease the cardiovascular risk. On the other hand,
there is a substantial lack of reliable information about
the benefits of primary prevention strategies aimed at
reducing the overall risk associated with diabetes. For all
these reasons, the evaluation of cardiovascular preventive
strategies in patients with diabetes represents a priority in
terms of public health.
Rationale to test the efficacy of aspirin for the prevention 
of cardiovascular events in diabetes mellitus
Data on primary prevention of cardiovascular events in
individuals with diabetes and no evidence of cardiovascu-
lar disease are scarce. The meta-analysis on the efficacy of
antiplatelet therapy showed a clear benefit for the whole
population of over 140.000 subjects (22% reduction in
the risk of major cardiovascular [CV] events), but no sta-
tistically significant benefit was documented in the sub-
group of about 5.000 diabetic patients (7% risk
reduction) [9]. More recently, an analysis on more than
1000 patients with diabetes enrolled in the Primary Pre-
vention Project (PPP) confirmed a non statistically signif-
icant reduction of 10% in the incidence of major CVTrials 2007, 8:21 http://www.trialsjournal.com/content/8/1/21
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events in individuals treated with aspirin as compared
with controls [10].
Another puzzling result regarding the efficacy of aspirin in
primary prevention comes from the recent data of Wom-
ens' Health Study [11] suggesting biological differences
between men in women in their response to aspirin. This
study showed that aspirin had no significant effect on the
risk of myocardial infarction or cardiovascular death nei-
ther in women without diabetes, nor in those with diabe-
tes.
The lack of adequate statistical power can represent the
more obvious explanation for the failure in documenting
a clear benefit of antiplatelet therapy in the primary pre-
vention of cardiovascular events in subjects with diabetes.
On the other hand, diabetes could represent a special case
of aspirin resistance [8], although no specific studies have,
to our knowledge, fully explored this hypothesis. The rea-
son for the apparently reduced aspirin efficacy in diabetic
patients remains largely unclear, however both, intra-
platelet mechanisms and extra-platelet inflammatory-
thrombogenic factors may contribute to the complexity of
aspirin failure in diabetic patients.
In high risk patients treated with aspirin, inadequate sup-
pression of Cox-1 as documented by high levels of serum
thromboxane-2 [12] or urinary thromboxane metabolites
[13], may be associated with increased risk of recurrent
cardiovascular events.
Moreover, in some cases the antiplatelet effects of aspirin
can be overwhelmed by aspirin-insensitive mechanisms
of platelet activation and thrombus formation, mainly
related to an up-regulated vascular inflammatory reaction
[8,14].
From this point of view, several studies have documented
that diabetes is associated with elevated levels of C-reac-
tive protein [15] and endothelial adhesion molecules,
considered as markers of the endothelial inflammatory
response [16,17]. Diabetes is also associated with a reduc-
tion in the production of, and sensitivity to nitric oxide
and PGI2, two of the most important antiaggregants. Fur-
thermore, an increased platelet sensitivity to aggregant
agents has also been described [18].
Rationale for association of aspirin and statins
It has been recently shown that platelet response to aspi-
rin is linearly reduced with increasing cholesterol plasma
levels. The presence of dyslipidemia, particularly com-
mon among diabetic patients, could thus be at least par-
tially responsible for a lower efficacy of aspirin in this
population [19]. The concomitant use of statins could
thus restore the normal platelet sensitivity to aspirin by
reducing cholesterol levels.
One additional reason to hypothesize a positive effect of
statins in improving platelet response to aspirin is related
to their anti-inflammatory properties. Several studies have
shown that treatment with statins is associated with a
decrease in the levels of C-reactive protein in just a few
weeks [20,21]. Statins also decrease the activity of inflam-
matory cells [22]. Clinical and experimental studies have
shown that statins can reduce endothelial dysfunction by
increasing the production of nitric oxide (NO), decreasing
the synthesis of endothelin-1 and inhibiting the LDL cho-
lesterol oxidation [23]. This class of drugs has also been
shown to increase atherosclerotic plaque stability by
reducing macrophage cholesterol accumulation and pro-
duction of metalloproteases [23]. Therefore, if an upregu-
lated vascular inflammatory reaction is responsible for
aspirin resistance, it is plausible to hypothesize that stat-
ins would also improve the clinical response to aspirin
therapy.
On the other hand, if platelets of diabetic patients were
normally inhibited by aspirin, but other thrombogenic
stimuli not inhibited by aspirin overwhelm aspirin action,
statins could exert a complementary action by inhibiting
these mechanisms; in fact, statins may exert antithrom-
botic effects by interfering with platelet adhesion and
aggregation, expression of tissue factor and plasminogen
activator inhibitor-1 (PAI-1), fibrinogen concentration
and blood viscosity [22].
Given these premises, it is of crucial importance to con-
duct a large-scale, pragmatic trial to evaluate the effective-
ness of aspirin use in primary prevention of
cardiovascular events in association with statins therapy
when included in a strategy of global risk control.
The choice of simvastatin is based on economical consid-
erations; in fact, Simvastatin is the only statin available in
Italy as an equivalent product, thus implying substantially
lower costs in comparison with brand products.
If the combination of aspirin and simvastatin will prove
to be effective in reducing diabetes morbidity and mortal-
ity, this will also translate into a dramatic decrease in the
costs for the Italian health care system.
Methods
General objective
Aim of this trial is to evaluate the efficacy of low-dose aspi-
rin (100 mg/daily) in the prevention of major cardiovas-
cular events in diabetic patients without clinically
manifest vascular disease and candidate for treatment
with statins. These preventive strategies will be evaluatedTrials 2007, 8:21 http://www.trialsjournal.com/content/8/1/21
Page 4 of 9
(page number not for citation purposes)
on the top of the other strategies (including lifestyle inter-
ventions and pharmacological treatments) aimed at opti-
mizing the care of diabetic patients in terms of metabolic
control and control of the other cardiovascular risk factors
(obesity, hypertension, and smoking).
Primary objectives
To assess the effects of low dose aspirin on the incidence
of major vascular events (defined as a combined end-
point of cardiovascular death, non-fatal myocardial inf-
arction, non-fatal stroke, or inpatient or outpatient hospi-
tal admission for cardiovascular causes, including acute
coronary syndrome, not planned revascularization proce-
dures, peripheral vascular disease), in a wide range of peo-
ple with type 1 or type 2 diabetes with no clinical evidence
of vascular disease and receiving statins treatment.
Secondary objectives
Additional aspects to be considered will include total and
cause specific mortality, venous thromboembolic epi-
sodes, major hemorrhagic episodes, and total number of
hospitalizations for cardiovascular causes (myocardial
infarction, stroke, acute coronary syndrome, not planned
revascularization procedures, heart failure, transient
ischemic attack, peripheral vascular disease, lower limb
revascularization procedures).
The study will also describe the natural history of the dis-
ease under routine clinical practice conditions, particu-
larly with reference to the degree of control of the other
cardiovascular risk factors.
The coherence in the effects of low dose aspirin across dif-
ferent patients subgroups defined according to their base-
line characteristics/risk (i.e. gender, age, type of diabetes,
metabolic control, baseline cholesterol levels, presence of
microvascular complications, treatment with other cardi-
ovascular drugs) will also be assessed.
Study design
This is a trial designed to assess whether 100 mg/daily of
aspirin prevent cardiovascular events in diabetic patients
without clinically manifest vascular disease and treated
with simvastatin (starting dose 20 mg/die).
A prospective, randomized, open, blinded endpoint eval-
uation (PROBE) design will be adopted [24].
Eligible patients will be randomly assigned (ratio 1:1) to
receive aspirin + simvastatin or simvastatin alone (Figure
1).
Study population
Male and female subjects aged ≥50 years are eligible for
the study if they meet the following inclusion criteria:
Inclusion criteria
• Written informed consent to participate in this study;
• Clinical diagnosis of type 1 or type 2 diabetes, based on
standard diagnostic criteria (Patients on treatment with
oral hypoglycaemic agents or insulin or with fasting
plasma glucose ≥126 mg/dl, confirmed on a second occa-
sion, or 2 hour post-challenge glucose (after 75 g OGTT)
≥200 mg/dl) irrespective of diabetes treatment;
• Need for statin treatment:
 Patients already receiving statin therapy irrespective of
their actual LDL cholesterol and total cholesterol levels or
 Patients not currently on statin treatment with LDL-cho-
lesterol levels ≥100 mg/dL (2.59 mmol/L) persisting after
three months of dietary advise (Threshold levels for the
initiation of statin treatment according to Third Joint Task
Force of European and other Societies on Cardiovascular
Disease Prevention in Clinical Practice [25]);
• Ability and willingness to comply with all study require-
ments.
Exclusion criteria
• Previous major vascular events (non-fatal myocardial
infarction, non-fatal stroke, angina, transient ischemic
attack, revascularization procedures, peripheral vascular
disease);
• Poor metabolic control (HbA1c > 14.0%);
• Any condition requiring elective treatment with aspirin;
• Contraindications to aspirin (history of aspirin allergy,
bleeding tendency, gastrointestinal haemorrhage or pep-
tic ulcer within six months, active hepatic disease, asthma,
renal failure, use of anticoagulant therapy.
• Contraindications to simvastatin (history of allergy,
chronic liver disease or abnormal liver function [i.e. ALT
or AST ≥1.5 times the upper limit of normal], severe renal
disease or evidence of renal impairment [i.e. creatinine >2
mg/dl], concomitant use of potent inhibitor of CYP3A4.
• Chronic use of non-steroidal anti-inflammatory drugs;
• Presence of any life-threatening condition;
• Child-bearing potential (pre-menopausal women not
using reliable contraception);
• History of active substance or alcohol abuse within the
last year.Trials 2007, 8:21 http://www.trialsjournal.com/content/8/1/21
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Participating centres
The study will be conducted by diabetes specialists and
general practitioners with a long experience of participa-
tion in clinical trials.
Study treatments
All randomized patients will be instructed to take one or
two tablets daily; in particular, if the patient will be
assigned to "aspirin+simvastatin arm", he will be
instructed to take one tablet containing simvastatin (one
20 mg tablet every evening), and the other containing
aspirin. Otherwise, the patient will be instructed to take
one tablet containing simvastatin.
Study drugs will be prescribed by the investigator.
An initial dose of 20 mg/daily of simvastatin will be pre-
scribed to patients not previously on treatment with stat-
ins.
The dose of simvastatin can be increased to 40 mg/day at
month 3 in those patients whose plasma LDL cholesterol
remains ≥100 mg/dL (2.59 mmol/L).
Patients already on statins treatment at study entry will be
shifted to the equivalent dose of simvastatin without the
need for a drug-free period.
Changes in simvastatin doses are allowed throughout the
study based on clinical judgment.
If target LDL cholesterol levels will not be reached with 40
mg/daily, clinicians may modify therapeutic strategies
(changes of statin, addition of other drugs such as
ezetimibe, fenofibrate, nicotinic acid, omega-3 fatty acid).
Treatment will be centrally assigned on telephone, after
verification of the correctness of inclusion and exclusion
criteria. A separate computer-generated randomization
table will be produced for each physician/diabetes centre
in random permuted blocks. Each randomized patient
will receive a unique subject identification number.
Sample size estimates
The sample size calculation is based on the cardiovascular
event rate occurred in over 1000 diabetic patients without
evidence of cardiovascular disease enrolled in the PPP
trial [10]. This study was conducted with the participation
of both General Practitioners and Diabetes Clinics in
Italy, thus closely reflecting the setting of care and the con-
text in which the ACCEPT-D trial will be conducted. In the
PPP trial the cumulative incidence of major cardiovascu-
lar events (cardiovascular death, myocardial infarction,
stroke, transient ischemic attack, peripheral vascular dis-
ease, revascularization procedures), after a median fol-
low-up of 4 years, was of 11.5% in subjects not assigned
to aspirin treatment (incidence rate of 2.88% per annum).
Assuming that treatment with statins can reduce such an
event rate by approximately one quarter (based on the
results of the meta-analysis of primary prevention studies
in patients with diabetes [26]), we can expect an incidence
rate of major cardiovascular events of about 2.1–2.2% per
annum. Since the primary cumulative end-point of the
study also includes hospitalizations for major vascular
causes, sample size calculations for the proposed trial are
based on a conservative estimated 2.5% annual rate of
major vascular events.
Aspirin has been shown to reduce major cardiovascular
events by about one quarter in a wide range of high risk
populations [27,28]. The sample size is thus estimated to
detect with a statistical power of 90% (α = 0.05) a reduc-
tion in the risk of major cardiovascular events of 25% (HR
= 0.75).
Given these assumptions, a total of 515 first events are
needed for the primary efficacy analysis. Therefore, the
total number of subjects to be enrolled is of 4.700
patients, to be followed up for five years. From the PPP
trial [29], it is possible to foresee a trial discontinuation
rate of 10%. Therefore, a total of 5.170 patients will be
enrolled (2.585 in each treatment arm). A total of 515
events will also ensure an adequate statistical power (i.e.
80%) to detect a smaller reduction in the risk of major
events (i.e. HR = 0.78).
Statistical analysis
All the efficacy analyses will be based on the intent to treat
population, consisting of all randomized patients.
Study design Figure 1
Study design.
Patients with type 1 and type 2 diabetes,
aged  ≥50 years without clinically manifest vascular disease
treated with simvastatin,
or with LDL cholesterol levels ≥100 mg/dL
persisting after three months of dietary advise
RANDOMIZATION
Aspirin 100 mg
+
Simvastatin 20 mg
Simvastatin 20 mg
Annual follow-up for end-points evaluation
Adoption of strategies aimed at optimizing the
control of other cardiovascular risk factors
(metabolic control, blood pressure control, smoking, etc.)Trials 2007, 8:21 http://www.trialsjournal.com/content/8/1/21
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Incidence rates (aspirin vs. no aspirin) will be estimated
using Kaplan-Meier survival curves that will be compared
using logrank analysis. Additionally, treatment efficacy
will be assessed by multivariate analyses using Cox's
regression model.
Other secondary analyses will include the evaluation of
efficacy of aspirin on all secondary end-points. Aspirin
efficacy will also be tested in the following different cir-
cumstances:
- Men vs. women;
- Age ≥65 vs. <65 years;
- Type of diabetes;
- Metabolic control (quartiles of HbA1c);
- Baseline cholesterol levels (quartiles of total and LDL-
cholesterol levels);
- Presence of microvascular complications (retinopathy,
nephropathy);
- Treatment with other cardiovascular drugs (in particular
β-blockers, ACE-inhibitors, Angiotensin Receptor Block-
ers).
The Mantel-Haenszel procedure will be applied to test for
the linearity of effects across subgroups, while the chi-
square test will be applied to test for heterogeneity of
effects among the subgroups.
Interim analyses
During the study one interim analysis will be performed
after the achievement of a number of events equal to 50%
of the planned number. Data will be analyzed with the
double scope of verifying the correctness of the assump-
tions made for sample size estimation regarding the pri-
mary end-point event rate (this information will be used
to provide guidance about the duration of follow-up),
and to perform a formal efficacy analysis.
The Steering Committee can decide whether to end or
modify the study if the comparisons in the study have pro-
vided "proof beyond reasonable doubt" (Appropriate cri-
teria of proof beyond reasonable doubt cannot be
specified precisely, but in general a difference of at least 3
standard deviations in an interim analysis of a major end-
point would be needed to justify halting, or modifying,
such a study prematurely [30]) that for all patients the
treatment is clearly indicated or clearly contraindicated in
terms of a net difference in incidence of major end-point,
or there will be evidence from other relevant trials or
meta-analyses that might reasonably be expected to influ-
ence materially the patient management of many clini-
cians who are already aware of the other main trial results.
Procedures
Visit schedule
After randomization, patients will be seen after three
months, after six months, and every six months thereafter,
to check tolerance and compliance to the trial treatments
and to reassess the presence and level of cardiovascular
risk factors and recording of outcome events.
All the patients should continue the protocol visit sched-
ule even in case of treatment interruption or after the
occurrence of one of the study events.
Data collection
For each randomized patient a minimum set of informa-
tion will be collected at study entry. This will include clin-
ical data regarding diabetes, cardiovascular risk factors,
and selected concomitant medications. Information on
laboratory parameters will also be collected, including
HbA1c, lipid profile, serum creatinine, albumin-creatinine
ratio, and liver enzymes. Investigators will be requested to
report the value of the last measurement performed. If the
last HbA1c  measurement was performed more than 3
months before randomization and all the other measure-
ments were performed more than 6 months before rand-
omization, the measurement should be performed again,
according to the standards of medical care for patients at
high cardiovascular risk. Laboratory data will be
abstracted from clinical records by the participating phy-
sicians and reported in ad hoc forms together with their
reference ranges.
The same set of information will be collected at 6-month
intervals, with the exception of albumin-creatinine ratio
that will be collected annually (Table 1).
The occurrence of any clinical event included in the end-
points will be notified. An independent ad hoc committee
of expert clinicians, identified by the Steering Committee,
will validate all the clinical events.
Moreover, information on any adverse event, including
side effects of study treatments, will be collected.
Timing
The duration of the enrolment phase will be of 18
months.
The total trial duration is event-driven. A total of 515 sub-
jects with a vascular event are required. A total duration of
follow-up of 5 years after the first randomized patient is
anticipated, if 5170 patients will be recruited and if theTrials 2007, 8:21 http://www.trialsjournal.com/content/8/1/21
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event rate will be of the same entity of that anticipated
(incidence of 2.5% per annum).
If the number of patients enrolled or the event rate will be
smaller, the duration of the follow-up will be prolonged
to allow the achievement of 515 events.
Ethical aspects
The study drugs are widely used in clinical practice and
their risk profile is well known. Drugs safety will be
closely monitored throughout the study.
Before starting the study, the protocol and/or other appro-
priate documents will be submitted to the Ethics Commit-
tee of the participating centres in accordance with the
local legal requirements (see Additional file 1).
The study will be conducted in accordance with the EC
guidelines for Good Clinical Practice and performed
according to the revised Declaration of Helsinki.
The trial was registered March 2007 at the International
Standard Randomized Controlled Trial Number Registra-
tion (ISRCTN48110081).
Patient information
A patient can be enrolled in the study only after a full dis-
cussion of all the aspects related to study design, implica-
tions for the patient, expected benefits and possible side
effects, in line with the content of the patient information
sheet, to be read and retained by the patient. The patient
will be given time to consider fully the information given
and will be encouraged to ask questions. If then he/she is
willing to participate in the trial, he/she will be asked to
sign a consent form.
Withdrawal from the study
A patient must be withdrawn from the study when judged
necessary by the responsible physician or when the
patient withdraws his/her informed consent. In these
instances all outcomes should be assessed.
Publication of the trial results
The trial results will be published by the members of the
Steering Committee, on behalf of all ACCEPT-D Study
Group. Before submission of any manuscript all local
principal investigators will have the opportunity to com-
ment on the manuscript.
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